Press Releases

Bitget Spreads Kindness This Ramadan by Providing 100,000 Meals to Those in Need

Comment(0)

Bitget Spreads Kindness This Ramadan by Providing 100,000 Meals to Those in Need Bitget Spreads Kindness This Ramadan by Providing 100,000 Meals to Those in Need VICTORIA, Seychelles, Feb. 28, 2025 (GLOBE NEWSWIRE) — Bitget, the leading cryptocurrency exchange and Web3 company, is partnering with world-renowned humanitarian organizations, including the UN Refugee Agency, UN World Food Programme, ShareTheMeal, and […]
Read more

Related Articles
Press Releases

Axi shares two new Axi Select milestones with $200K trader payout and seven new $1M-funded Pro M traders

Asianet Pakistan

SYDNEY, March 09, 2026 (GLOBE NEWSWIRE) — Axi, a financial leader in online CFD and FX trading, has announced two Axi Select milestones – a $200K monthly payout achieved by an Acceleration-stage trader and the progression of seven traders to Pro M status – the capital allocation program’s highest tier – each unlocking access to […]
Press Releases

ROSEN, NATIONAL TRIAL COUNSEL, Encourages Kyndryl Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – KD

Asianet Pakistan

NEW YORK, March 14, 2026 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Kyndryl Holdings, Inc. (NYSE: KD) between August 7, 2024 and February 9, 2026, both dates inclusive (the “Class Period”), of the important April 13, 2026 lead plaintiff deadline in the securities class action first filed […]
Press Releases

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting

Asianet Pakistan

DALY 2-EU results show zamtocabtagene autoleucel (zamto-cel) demonstrated clinically meaningful superiority over chemoimmunotherapy in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL)1 Zamto-cel was well-tolerated in the majority of patients. DALY 2-EU included a high-risk study population, characterized by older age and clinically high-risk disease features A 12-day manufacturing time resulted in a vein-to-vein time […]